Drug Combination Prevents Clots Without Increasing Bleeding in Mouse Models

Researchers continue to hone in on how best to prevent blood clots, which cause strokes and heart attacks, without unintended side effects.

3:18 PM

Author | Haley Otman

drawing in blue ink of pills on lined paper with yellow badge on bottom right that says lab note
Credit: Michigan Medicine

A new approach to preventing blood clots, and thus more serious cardiovascular events like stroke, was successful in mouse models without causing major bleeding events.

"It's the only selective inhibitor to block activation of 12-lipoxygenase in the human platelet and prevent blood clots from forming," says study author Michael Holinstat, Ph.D., an associate professor of pharmacology, internal medicine and surgery at Michigan Medicine.

The researchers delivered the new drug, which they call ML355, by combining it with synthetic high density lipoprotein, or sHDL, for this proof-of-concept investigation. First, they tested this in human blood, and then in mouse models. The combination allowed for more precision than most of the antithrombotics currently available.

"We were able to potently and selectively target regions of inflammation and injury in the blood vessel in order to prevent blood clots and thrombosis from occurring," Holinstat says. "The millions of people with cardiovascular disease in the U.S. would benefit greatly from a lower-risk option to avoid thrombosis."

Holinstat adds that this discovery was successfully translated from identification of a critical target in the platelet regulating thrombosis to clinical trials, recently receiving orphan drug designation from the U.S. Food and Drug Administration for prophylactic treatment of heparin-induced thrombocytopenia (HIT). The FDA approved the Investigational New Drug application, and ML355 will begin clinical trials for novel treatment of patients suspected of HIT in March.

Disclosure: ML355 is licensed by Veralox Therapeutics as VLX-1005. Holinstat is a shareholder in Veralox Therapeutics. He also invented ML355 (U.S. patent no. US10,266,488; Japan patent no. 6463366).

Paper cited: "Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice," Science Advances. DOI: 10.1126/sciadv.abd0130

More Articles About: Lab Notes stroke Deep Vein Thrombosis (DVT) Stroke Prevention Heart Attack Treatment Drug Discovery Basic Science and Laboratory Research Cardiovascular: Diseases & Conditions
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories Animated microscopic image of the glioblastoma's tumor microenvironment
Health Lab
New model of key brain tumor feature could help scientists understand how to develop new treatments
Model shows how oncostreams form and behave in brain tumors – and how to inhibit them
Illustration of scientists and doctors playing basketball in white coats and scrubs
News Release
Four U-M teams selected for virtual tournament of science
U-M researchers' work made the bracket in the 2024 STAT Madness tournament of science, and need public support to advance
Adult performs CPR on a young athlete, illustration with red and blue figures
Health Lab
Sudden cardiac arrest in young athletes: 5 things parents should know
Sudden cardiac arrest in young athletes: 5 things parents should know
Graphic showing pills, a heart and brain with data on aspirin use
Health Lab
Aspirin can prevent a second heart attack or stroke, but many don’t use it
Washington University School of Medicine and Michigan Medicine researchers found that fewer than half of people who have experienced a heart attack or stroke use aspirin to prevent a second one.
Jianping Fu, Ph.D., Professor of Mechanical Engineering at the University of Michigan and the corresponding author of the paper being published at Nature discusses his team’s work in their lab with Jeyoon Bok, Ph.D. candidate at the Department of Mechanical Engineering.
Health Lab
Human stem cells coaxed to mimic the very early central nervous system
The first organized stem cell culture model that resembles all three sections of the embryonic brain and spinal cord could shed light on developmental brain diseases
Illustration of a microscope
Health Lab
Hippo signaling pathway gives new insight into systemic sclerosis
Study focuses on Hippo signaling pathway as critical link between fibrosis, vascular dysfunction, and sex bias in systemic sclerosis